Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody.
Seckinger A, Buatois V, Moine V, Daubeuf B, Richard F, Chatel L, Viandier A, Bosson N, Rousset E, Masternak K, Salgado-Pires S, Batista C, Mougin C, Juan-Bégeot F, Poitevin Y, Hose D.
Seckinger A, et al. Among authors: rousset e.
Front Immunol. 2024 Apr 24;15:1378813. doi: 10.3389/fimmu.2024.1378813. eCollection 2024.
Front Immunol. 2024.
PMID: 38720892
Free PMC article.